The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 12, 2016

Filed:

Aug. 12, 2014
Applicants:

Shi-lung Lin, Arcadia, CA (US);

David T S Wu, Arcadia, CA (US);

Inventors:

Shi-Lung Lin, Arcadia, CA (US);

Yi-Wen Lin, Cerritos, CA (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/26 (2006.01); A61K 31/713 (2006.01); A61K 31/7105 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 47/26 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 2310/141 (2013.01); C12N 2320/32 (2013.01); C12N 2330/50 (2013.01); C12N 2330/51 (2013.01); C12N 2740/15041 (2013.01);
Abstract

This invention relates to a composition and its use for formulating nucleic acid-based drugs/vaccines with sugar alcohol compositions into complexes for both in-vitro and in-vivo delivery. Particularly, the present invention includes the ingredients and processes necessary for formulating therapeutic and pharmaceutical nucleic acid compositions, such as miRNA, microRNA precursors, shRNAs, siRNAs, ribozymes, antisense RNAs/DNAs, RNA-DNA hybrids and DNA vectors/vaccines, with glycylated sugar alcohols/sugars into delivery complexes, which can then be absorbed by cells in vivo and in vitro via active endocytosis. Also, the present invention discloses that chemical compounds containing sugar alcohol- and/or sugar-like structures can protect nucleic acids, in particular miRNAs, shRNAs, siRNAs and ribozymes, from degradation in vivo as well as in vitro. Therefore, the present invention is also a formula and method for preserving the structural integrity and functional efficacy of these nucleic acid-based drugs and/or vaccines in vivo and in vitro.


Find Patent Forward Citations

Loading…